Inhibition of BCR-ABL1 kinase by imatinib prevents SMAD4 tyrosine phosphorylation and re-sensitises CML cells to TGF-β-induced anti-proliferative and pro-apoptotic responses [133]. The gene discussed is SMAD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.